Dr. Alex Wolff
Executive Chairman & Director
Dr. Alex Wolff is Executive Chairman and co-founder of CRC, which developed the first oncolytic therapy which was approved in the U.S. and Europe in 2013. Alex relocated the Company from the US to Canada in 2002. Subsequently he established their infrastructure including the world’s largest gene therapy manufacturing facility and now serves as the Company’s Chairman. Alex is also currently a Venture Partner at Oxygen. Alex received a Phd in Cellular and Molecular Pathology from Loughborough University UK, and was a healthcare investment banker with HSBC H&Q.